Investing in the Future of Health Care with Mike Taylor

Episode Summary

Executive Summary: Michael Taylor, manager of Simplify’s Healthcare ETF (PINK), discussed his science-to-investing background, the fund’s charitable structure, and a bottom-up healthcare stock-picking process focused on timing, revisions, and avoiding binary risk. He highlighted innovation in drugs, med tech, and care delivery, sees major long-term opportunities in GLP-1s, cancer treatment, and aging science, and warned that macro risks like inflation, deglobalization, and heavy government spending could pressure markets ahead.

Main Topics: PINK ETF’s charitable impact structure (Priority: 5/5): Taylor explained that PINK is designed as a true impact-investing vehicle: net fees and his compensation are donated to Susan G. Komen, aligning investor returns with charitable giving. From molecular biology to healthcare investing (Priority: 5/5): He described his transition from lab-based drug development and virology/gene therapy work into Wall Street, driven by frustration with scientific timelines and a desire for broader impact and better economics. Healthcare sector framework and stock-picking process (Priority: 5/5): Taylor organizes healthcare into three buckets—drugs, med tech, and care delivery/tools—and emphasizes a bottoms-up process based on differentiated insight, earnings revisions, and timing rather than top-down screens. Innovation themes in healthcare (Priority: 5/5): He argued healthcare is in a renaissance, pointing to faster R&D cycles, better models, GLP-1 obesity drugs, rare-disease breakthroughs, cancer progress, and future work on aging biology. Risk management and binary outcomes (Priority: 4/5): Taylor stressed that healthcare investing is shaped by binary clinical and regulatory events, especially in drugs, and that managing position size and timing matters as much as being directionally right. Macro outlook and policy concerns (Priority: 4/5): He warned about sticky inflation, deglobalization, looming refinancing stress, commercial real estate problems, and the likelihood that policymakers will keep printing money, which could support stocks but worsen long-term distortions.

Key Arguments: PINK is structured as a genuine impact-investing ETF because fees and Taylor’s compensation go to Susan G. Komen, linking performance with charity. A scientist’s background can be an edge in healthcare because it helps identify scientific hurdles and end-market realities that others miss. In healthcare, being right is not enough; investors must also get timing right because stocks can move far before fundamentals are recognized. Healthcare is best understood as three broad segments: drugs, med tech, and care delivery/tools, with each having different economics and risks. The biggest opportunities come from meaningful earnings revisions driven by new products, pricing changes, or market expansion, not from simple valuation screens. Binary risk is especially important in pharmaceuticals because clinical, safety, or regulatory surprises can destroy value quickly and unpredictably. GLP-1s are a major long-term category with multiple downstream benefits beyond weight loss, and Lilly and Novo Nordisk currently dominate the space. Cancer is likely to become more manageable over the next 20 years, more like a chronic condition than a fatal diagnosis in many cases. Aging biology may be the next giant healthcare frontier, with quiescent cells likely a major target for extending healthspan. Macro risks—deglobalization, higher borrowing costs, and government spending limits—could become more visible in 2025 and shift market behavior. Valuation alone is unreliable in this environment; the key is understanding when valuation matters versus when policy and liquidity overwhelm it.

Data Points: ETF charity structure: 100% of net fees and compensation - Taylor said PINK’s net fees and his compensation go to Susan G. Komen. Healthcare innovation share: ~95% - Taylor claimed the U.S. produces about 95% of healthcare innovation. Drug development timeline reduction: 2–3 years vs. 7 years - He said modern science can take a concept from whiteboard to clinic in 2–3 years versus about 7 years in the past. Phase III failure rate: Very rare - Taylor said phase III failures are now uncommon because compounds are better understood before late-stage trials. Patent life: 15–17 years - He noted drugs generally go off patent in this timeframe, after which prices usually fall substantially. GLP-1 development age: 7 years ago - He said GLP-1s were available about seven years ago, but dosing improvements expanded their usability. Multiple myeloma survival: 5 years historically - He said patients used to die within about five years before newer therapies improved outcomes. Position size in Cooper Companies: 4% overnight / 5% current - Taylor described buying a roughly 4% position quickly and later increasing to about 5% after a strong quarter. Expected growth for Cooper Companies: 8% street estimate vs. 11–12% needed - He said consensus estimates were too low and should be in the low double digits. Thermo Fisher valuation: 25x forward earnings - Taylor cited Thermo Fisher trading at roughly 25 times forward earnings with single-digit growth. Apple valuation comparison: 24x forward earnings - Used as a comparison point to show broad market valuation distortions. Inflation outlook: 3%+ - He expects inflation to remain sticky around 3% or above. Federal borrowing need: $30 trillion - Taylor said the U.S. government may need to borrow roughly this amount over the next 10 years. Foreign financing share: ~45% - He said about 45% of future borrowing may need to come from overseas investors. Government overspending: $2.5 trillion - He referenced a need to overspend by about $2.5 trillion to support the economy/policy goals.

Pivotal Quotes: "PINK is the only ETF, to my knowledge, that is of the true essence of impact investing, where the fees, the net fees, and my compensation all go to the Susan G. Komen Foundation for Breast Cancer." — Michael Taylor: Explaining the fund’s charitable structure and mission. "The most important thing to being a successful investor is booking your gains." — Michael Taylor: Final advice to retail investors and the closing lesson of the episode. "When you got the nuts, you got to go big." — Michael Taylor: Describing how he sizes positions when he has a strong, differentiated edge.

Implications: Healthcare investors should prioritize scientific insight, timing, and risk control over simple valuation or factor screens. The sector’s innovation pipeline is strong, but policy, pricing, and macro conditions may shape returns materially over the next few years.